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 
Abstract— Abstract— Type 2 diabetes (T2D) is a long-term metabolic disorder. A pilot trial was designed to investigate the effects 
of the long acting insulin Detemir on endogenous insulin secretion, to assess use in early T2D care. Provesn metabolic system models 
are used to identify patient-specific insulin sensitivity and endogenous insulin secretion from clinical data. Post-cardiac surgery 
patients with early T2D or pre-diabetes based on HbA1c were given a bolus of insulin Detemir on one day, and none on the second 
day in hospital. Blood glucose, insulin, C-Peptide, and all nutrition given are recorded. Early results from N=3 patients show 0.8-
1.0U/hour insulin Detemir doses have no apparent suppression of endogenous insulin secretion, but does help lower glucose levels. 
The results show the model captures glucose-insulin dynamics in pre-diabetic post-surgical patients, and insulin Detemir may be 
useful to support individuals with pre-diabetes in reducing blood glucose levels. Tests with higher doses, need to be carried out to 
verify these results over a greater range of patients. 
I. INTRODUCTION 
Type 2 diabetes (T2D) is a long-term metabolic disorder characterised by insulin resistance, hyperglycaemia, and reduced 
endogenous insulin secretion. The overall prevalence of T2D of approximately 366 million in 2011 is expected to rise to 552 
million by 2030 [1], with significant costs of ~1% GDP rising to 1.5% or more by 2030. Its scale and cost is a dominant factor 
in the growing need to find ways to delay the incidence and increasingly costly progression of T2D. 
Insulin Detemir is a long-acting insulin designed to provide a basal plasma insulin rate, modified by an added long-chain 
fatty acid which binds to albumin in plasma, existing in rapid equilibrium in bound and unbound states with ~2-4 % unbound at 
any time [2, 3]. Only in the unbound state is insulin Detemir free to facilitate cellular glucose uptake. The appearance and bio-
availability of Insulin Detemir has not been previously modelled. 
The ORIGIN study [4] investigated the effects of long acting insulin glargine and insulin therapy on a range of health 
outcomes. A key result was the use of insulin, even with low compliance, reduced the incidence of progression from pre-diabetes 
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to T2D. Given even a single year delay in incidence can have significant overall cost and quality of life outcomes [5], this result 
indicates a potential role for early insulin use as basal support in pre-diabetes. In contrast, insulin therapy is currently a “last 
resort” drug in T2D for safety reasons [6]. 
This study presents an analysis of pilot results from a trial using Detemir in pre-diabetic patients. The trial goal is to assess 
the impact of Detemir as a basal analogue to support (without suppressing) pancreatic, as a first step in studying early use of long 
acting insulin to delay progression from pre-diabetes to T2D. This analysis uses model-based methods to model the appearance 
of bio-available Detemir, and assess its effect on insulin secretin. 
II. MODELLING 
Mathematical compartment models incorporating patient glucose-insulin data and enabling endogenous insulin production 
estimation are adapted from previous work [7, 8].  
A. Gastrointestinal Model 
Glucose appearance following meal ingestion is described by a gastrointestinal model [9], describing solid (𝑞𝑠𝑡𝑜1, mmol) and 
liquid (𝑞𝑠𝑡𝑜2, mmol) glucose content of a meal in the stomach, and the glucose in the intestines (𝑞𝑔𝑢𝑡, mmol): 
?̇?𝑠𝑡𝑜1 = 𝐷(𝑡) − 𝑘21 ∙ 𝑞𝑠𝑡𝑜1 (1) 
?̇?𝑠𝑡𝑜2 = 𝑘21 ∙ 𝑞𝑠𝑡𝑜1 − 𝑘𝑒𝑚𝑝𝑡(𝑞𝑠𝑡𝑜) ∙ 𝑞𝑠𝑡𝑜2 (2) 
?̇?𝑔𝑢𝑡 = 𝑘𝑒𝑚𝑝𝑡(𝑞𝑠𝑡𝑜) ∙ 𝑞𝑠𝑡𝑜2 − 𝑘𝑎𝑏𝑠 ∙ 𝑞𝑔𝑢𝑡  (3) 
The rate of glucose appearance in blood plasma, (𝑅𝑎) is: 
In Equations 1-4, 𝐷(𝑡) is the rate of delivery of glucose or 
carbohydrates into the stomach, estimated by dividing meal 
size by duration. Note, 𝑓 ≤ 1 is a scaling factor for incomplete absorption and first-pass hepatic clearance.  
The stomach emptying rate, 𝑘𝑒𝑚𝑝𝑡 (𝑚𝑖𝑛
−1),  is a function of the size of the meal remaining in the stomach relative to the 
total meal size, 𝐷𝑡𝑜𝑡 , and defined: 
𝑞𝑠𝑡𝑜 = 𝑞𝑠𝑡𝑜1 + 𝑞𝑠𝑡𝑜2 (5) 
𝑅𝑎 = 𝑓 ∙ 𝑘𝑎𝑏𝑠 ∙ 𝑞𝑔𝑢𝑡  (4) 




𝛼 =  tanh[𝛼(𝑞𝑠𝑡𝑜 − 𝑏 ∙ 𝐷𝑡𝑜𝑡)] 









2 ∙ 𝐷𝑡𝑜𝑡 ∙ 𝑐
 (7) 
 
Figure 1. Depiction of 𝑘𝑒𝑚𝑝𝑡 as a function of 𝑞𝑠𝑡𝑜 for a 35 g carbohydrate meal. Horizontal dashed lines from top-bottom indicate the maximum, mean and 
minimum emptying rates. 
𝐷𝑡𝑜𝑡  = 10
−3 is used during fasting to avoid singularity. Figure 1 describes the dynamics of Equation 5 as stomach glucose 
quantities change over time for 35g carbohydrate. Further parameter values and definitions are found in Table 1. 
B. Glucose-Insulin Modelling 
Blood glucose, G (mmol/L), and plasma, I (mU/L), and interstitial insulin, Q (mU/L), dynamics are modelled [7]: 
?̇? = −𝑝𝑔(𝐺 − 𝐺𝑓𝑎𝑠𝑡) − 𝑆𝐼
𝐺(𝑄 + 𝑄𝐷𝐹)
1 + 𝛼𝐺(𝑄 + 𝑄𝐷𝐹)
 
+




𝐼̇ = −𝑛𝐾 ∙ 𝐼 − 𝑛𝐿
𝐼
1 + 𝛼𝐼𝐼




?̇? = 𝑛𝐼(𝐼 − 𝑄) − 𝑛𝑐
𝑄
1 + 𝛼𝐺 ∙ 𝑄
 (11) 
Insulin sensitivity (𝑆𝐼) and fasting blood glucose (𝐺𝑓𝑎𝑠𝑡) are time dependant. 𝐺𝑓𝑎𝑠𝑡  for each day was the first glucose 
measurement prior to breakfast. SI is a time varying parameter is identified from data. 𝑈𝑒𝑛 is pancreatic secretion rate, estimated 
from C-peptide measurements [10] and 𝑄𝐷𝐹 represents additional insulin from the Detemir analogue,. All other parameter values 
are detailed in Table 1.  
C. Insulin Detemir Model 
A seven-compartment model is used for Detemir kinetics, where injected Detemir is hexameric (𝐼𝐷𝐻 , 𝑚𝑈), and dissociates 
into dimeric and monomeric insulin: 
  
𝐼?̇?𝐻 = −𝑘𝑎 ∙ 𝐼𝐷𝐻 + 𝐼𝑏𝑜𝑙𝑢𝑠  (12) 
?̇?𝐷𝐹,𝑙𝑜𝑐𝑎𝑙 = 𝑘𝑎𝐼𝐷𝐻 − 𝑄𝐷𝐹,𝑙𝑜𝑐𝑎𝑙(𝑘𝑏 + 𝑘𝑑𝑖) − 
(𝑘𝑑1 ∙ 𝑄𝐷𝐹,𝑙𝑜𝑐𝑎𝑙 − 𝑘𝑑2 ∙ 𝑄𝐷𝐵,𝑙𝑜𝑐𝑎𝑙) 
(13) 
?̇?𝐷𝐵,𝑙𝑜𝑐𝑎𝑙 = 𝑘𝑑1 ∙ 𝑄𝐷𝐹,𝑙𝑜𝑐𝑎𝑙 − 𝑘𝑑2 ∙ 𝑄𝐷𝐵,𝑙𝑜𝑐𝑎𝑙  (14) 
Where 𝐼𝑏𝑜𝑙𝑢𝑠 (𝑚𝑈) is the subcutaneously injected insulin. Free and albumin bound insulin in the local depot are 𝑄𝐷𝐹,𝑙𝑜𝑐𝑎𝑙   (𝑚𝑈) 
and 𝑄𝐷𝐵,𝑙𝑜𝑐𝑎𝑙   (𝑚𝑈), 𝑘𝑑1  and 𝑘𝑑2 are rate constants defining binding and unbinding to albumin. The values for 𝑘𝑑1  and 𝑘𝑑2 
ensure 4% unbound Detemir at steady state [11]. Further parameter values, units, and definitions are in Table 1. 
The model uses four compartments to describe free and bound Detemir insulin in both blood plasma and the whole body 
interstitial fluid compartment. 
TABLE I: PARAMETER VALUES AND UNITS 
Parameter Value Unit Ref 
Gastrointestinal Model 
𝒌𝟐𝟏 Stomach grinding 0.054 𝑚𝑖𝑛
−1 [9] 
𝒌𝒂𝒃𝒔 Gut adsorption of glucose 0.071 𝑚𝑖𝑛
−1 [9] 
𝒃 Parameters describing stomach 
emptying. See text for details. 
0.69 − [9] 





𝒇 Scaling factor 0.8 − [9] 
Insulin Detemir Model 
𝒌𝒂 hexameric dissociation into 
dimers and monomers 
 0.0078 𝑚𝑖𝑛−1 [12] 
𝒌𝒅𝟏 rate constants defining the 
binding and unbinding of the 
insulin to albumin 
0.96 𝑚𝑖𝑛−1 [12] 
𝒌𝒅𝟐 0.04 𝑚𝑖𝑛
−1 [12] 
𝒌𝒅𝒊 degradation of Detemir in the 
local interstitium 
0.0594 𝑚𝑖𝑛−1 [12] 
𝒌𝒃 diffusion of unbound insulin 
from local depot to blood 
0.0181 𝑚𝑖𝑛−1 [12] 
𝒏𝑲 renal clearance of Detemir 0 𝑚𝑖𝑛
−1 [12] 
𝒏𝑫𝑳 ∗ Detemir liver clearance 0.288 𝑚𝑖𝑛
−1 [12] 
𝒏𝑫𝑰 Detemir trans-endothelial 0.06 𝑚𝑖𝑛
−1 [12] 
  
* this is the sum of renal and hepatic clearance rates 
** these constants are physiologically identical and are 0.5x the displayed 
value due to cardiac surgery patients having reduced kidney clearance 
 
𝐼𝐷𝐹is the unbound insulin in blood plasma, 𝐼𝐷𝐵 the bound 
insulin in plasma, 𝑄𝐷𝐹 is unbound insulin in interstitial fluid. 




𝑄𝐷𝐹,𝑙𝑜𝑐𝑎𝑙 − 𝐼𝐷𝐹(𝑛𝐷𝐿 + 𝑛𝐾) 
−𝑛𝐷𝐼(𝐼𝐷𝐹 − 𝑄𝐷𝐹) − (𝑘1 ∙ 𝐼𝐷𝐹 − 𝑘2 ∙ 𝐼𝐷𝐵) 
(15) 
𝐼?̇?𝐵 = 𝑘1 ∙ 𝐼𝐷𝐹 − 𝑘2 ∙ 𝐼𝐷𝐵  (16) 
?̇?𝐷𝐹 = −𝑛𝐷𝐶 ∙ 𝑄𝐷𝐹 + 𝑛𝐷𝐼(𝐼𝐷𝐹 − 𝑄𝐷𝐹) 
−(𝑘1 ∙ 𝑄𝐷𝐹 − 𝑘2 ∙ 𝑄𝐷𝐵) 
(17) 
?̇?𝐷𝐵 = 𝑘𝑑1 ∙ 𝑄𝐷𝐹 − 𝑘𝑑2 ∙ 𝑄𝐷𝐵  (18) 
Further details are in Table 1. 
D. Endogenous Insulin Secretion 
C-peptide is secreted in equimolar quantities with insulin, 
but only cleared by the kidney, providing a convenient means to 
estimate endogenous insulin secretion using a model  describing 
plasma (𝐶, 𝑝𝑚𝑜𝑙/𝐿) and peripheral (𝑌, 𝑝𝑚𝑜𝑙/𝐿) C-peptide 
concentrations [10]: 
?̇? = 𝑈𝑒𝑛 − 𝐶(𝑘1 + 𝑘3) + 𝑘2 ∙ 𝑌 (8) 
?̇? = 𝑘1 ∙ 𝐶 − 𝑘2 ∙ 𝑌 (9) 
Further details are in Table 1. Eqs 19-20 can be solved for Uen: 
𝑈𝑒𝑛 = −𝑘1𝐶(𝑡0) ∙ exp[−𝑘2(𝑡 − 𝑡0)]   
+k1k2 ∫ 𝐶(𝑠) ∙ exp[−𝑘2(𝑡 − 𝑠)] 𝑑𝑠
𝑡
𝑡0
+ ?̇? + 𝐶(𝑘1 + 𝑘3) 
(10) 
Endogenous secretion, 𝑈𝑒𝑛, can then be input to Equation 10. 
diffusion 
𝒏𝑫𝑪 Detemir: peripheral 
degradation 
0.032 𝑚𝑖𝑛−1 [12] 
Glycaemic Control Model 
𝒑𝒈 the non-insulin mediated 
uptake 
0.06 𝑚𝑖𝑛−1 [8] 
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𝑽𝑮 Glucose volume of distribution  0.18𝑚 𝐿 [8] 
𝒏𝑲 ∗∗ Kidney clearance of insulin 0.0644 𝑚𝑖𝑛
−1 [8] 
𝒏𝑳 Hepatic insulin clearance  0.15 𝑚𝑖𝑛
−1 [8] 
𝜶𝑰 Saturation of liver clearance 0.0017 𝐿 ∙ 𝑚𝑈
−1 [8] 
𝒙𝑳 First-pass hepatic insulin 
clearance 
0.67 − [8] 
𝒏𝑪 Insulin: Peripheral degradation 0.032 𝑚𝑖𝑛
−1 [8] 
𝑽𝑰 Insulin volume of distribution 0.038𝑚 𝐿 [8] 
𝒏𝑰 Insulin trans-endothelial 
diffusion 
0.006 𝑚𝑖𝑛−1 [8] 
𝜶𝑮 Saturation of insulin binding to 
cells 
0.0154 𝐿 ∙ 𝑚𝑈−1 [8] 
Endogenous Insulin Secretion 
𝒌𝟏 C-peptide: diffusion between 
central and peripheral 
compartments 
0.0478 𝑚𝑖𝑛−1 [10] 
𝒌𝟐 0.0516 𝑚𝑖𝑛
−1 [10] 
𝒌𝟑 ∗ Clearance of C-peptide 0.0644 𝑚𝑖𝑛
−1 [10] 
  
E. Insulin Sensitivity Identification 
Glucose, insulin dose and meal data enable patient-specific insulin sensitivity to be identified via integral-based methods [13, 
14]. A 6-hourly insulin sensitivity was identified based on data density and to observe changes over a 24-hour period. 
III. CLINICAL TRIAL 
Glycaemic data was obtained from patients enrolled in a two-day pilot trial using insulin Detemir following elective cardiac 
surgery at St George’s Hospital, Christchurch, New Zealand. Ethical consent was obtained from the NZ National Health and 
Disability Ethics Committee. Inclusion criteria was pre-operative HbA1c > 40 𝑚𝑚𝑜𝑙/𝐿. N=4 patients were enrolled to date, but 
1 had consent withdrawn, giving N=3 for this study. Patient demographics are in Table 2.  
Each patient received 0.25 𝑈/𝑘𝑔 of insulin Detemir the morning of the first day, while no dose is given on the second. Blood 
samples were taken at -60, 30, 60 and 120 minutes around each meal, and assayed for C-peptide and insulin concentrations 
(Roche Elecsys), converting plasma insulin concentrations using 1 μU/mL = 6.00 pmol/L [15]. The amount eaten in each meal 
was estimated from a photograph before and after each meal, with nutritional information given by the hospital. Any snacks 
were recorded in hospital notes. 
IV. RESULTS 
Identified model fit to data for Patients 1-3 are shown in Figures 2, and summarized in Table 3. Overall model fit is good for 
Patients 1 and 2, with the model capturing all major peaks/trough dynamics. RMS error is 1.1 – 1.4 mmol/L in these patients, 
with slight timing mismatch around peaks contributing to most errors. 
RMS error to measured insulin data is larger, as some peak magnitudes timing mismatches mean vertical error is large, even 
if horizontal error is qualitatively good. This error is anticipated as no parameter is specifically fit to this insulin data, and the fit 
quality is merely a measure of the endogenous secretion modelled and the modelled Detemir insulin appearance. Overall, it 
appears no major dynamics are missing from the model. 
Model fit to Patient 3 is reasonable for plasma insulin, but worse for plasma glucose. From Figure 2b) may be that plasma 
glucose is persistently high with very little meal response, or additional unrecorded meals are consumed. This patient also 
displays very low insulin secretion relative to Patients 1 and 2, and has no first phase secretion, which is typically indicative of 
T2D, and matches their much higher HbA1c in Table 2 of 68mmol/mol.  
  
Focusing only on pre-diabetes Patients 1-2, identified 6-hourly insulin sensitivity is consistent with normal glucose tolerance 
(10.8 × 10−4 𝐿𝑚𝑈−1𝑚𝑖𝑛−1) to impaired glucose tolerance (6.9 × 10−4 𝐿𝑚𝑈−1𝑚𝑖𝑛−1) [16], matching their pre-diabetes 
HbA1c of 41 and 43 mmol/mol in Table 2 [17]. 
Examining endogenous insulin suppression by exogenous insulin Detemir, the total insulin secreted is compared in Table 4 
for pre-diabetes Patients 1-2. Insulin secreted is similar for both days, irrespective of the presence of insulin Detemir. Meal-
normalized insulin secretion in Table 4 shows secretion per carbohydrate gram (effectively insulin sensitivity) is much higher 
on Day 2 without insulin Determir, despite increasing recovery. Thus, adding insulin Detemir does not appear to suppress insulin 
secretion, and aids glucose uptake. 
V. DISCUSSION AND CONCLUSIONS 
The model developed here extends previous models with a novel insulin Detemir model [12] for pre-diabetes and T2D. 
Overall, model fit to initial data indicates the model captures all observed dynamics well. It does not initially appear that insulin 
Detemir has any suppressive effect on endogenous insulin production. Since only 2-4 % of the insulin Detemir is unbound at 
any time (~21 𝑚𝑈 on average) any effect would likely be minimal and insufficiently large to affect pancreatic secretion [18]. 
Future trials should assess higher insulin Detemir doses.  
Perhaps the largest error source is meal consumption estimation, which has magnitude and timing error. Insulin secretion rates 
were 34-240mU/min and 34-320mU/min for Patients 1-2, respectively. Secretion rates as high as 464mU/min were obtained 
[19] in a similar cohort, suggesting the rates here are physiologically possible. Equally, these patients are likely more insulin 
resistant post-surgery, which could be reflected in higher secretory rates. 
TABLE II: PATIENT DEMOGRAPHICS FOR THE CLINICAL TRIAL. 








1 73 M 88 27.2 22 41 
2 74 F 72 27.1 18 43 
3 75 M 88 29.1 22 68 
TABLE III: RMS ERROR FROM MODEL FIT TO CLINICAL DATA. 
TABLE IV: EFFECT OF INSULIN DETEMIR ON PANCREATIC FUNCTION 
 Patient 1 Patient 2 
 Day 1 Day 2 Day 1 Day 2 
Total insulin production (U) 85.4 87.5 101 99.4 
Average secretion rate (mU/min) 117 121 143 131 
Patient Glucose RMS Insulin RMS 
1 1.105 𝑚𝑚𝑜𝑙/𝐿 506.0 𝑝𝑚𝑜𝑙/𝐿 
2 1.425 𝑚𝑚𝑜𝑙/𝐿 553.7 𝑝𝑚𝑜𝑙/𝐿 
3 3.13 𝑚𝑚𝑜𝑙/𝐿 82.1 𝑝𝑚𝑜𝑙/𝐿 
  
Detemir dose (U) 22.0 − 18.0 − 
Meal Size (g carb) 179 262 160 248 
Meal-normalised production (U/g) 0.48 0.33 0.63 0.40 
 Overall, the model readily captures observed glucose-insulin dynamics in glucose responsive patients, and enables potentially 
novel approaches to early insulin use to delay onset of T2D from pre-diabetes.  
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